OXFORD

The Oxford-Harrington Rare Disease Centre Launches Pioneering Therapeutics Accelerator to Advance Innovative Treatments for Rare Diseases

Retrieved on: 
Tuesday, October 3, 2023
Partnership, Disease, Drug development, University, Therapy, 100,000 Genomes Project, Rare disease, University Hospitals Cleveland Medical Center, Hope, University of Oxford, Research, Genomics, OHC, OXFORD, DSM-IV codes, Translation, Oxford Sciences Enterprises, MD, Patient, Investment, Cancer, Genomics England, Department of Biology, University of Oxford, Motivation, Accelerator, Foreign policy, Rare, Courage, Family, Harrington, Pharmaceutical industry, Hospital, Nursing, Vaccine, Management, Neuroscience, Medicine, Pediatrics

Former U.K. Prime Minister David Cameron to lead the international efforts of the Accelerator as Chair of the Oxford-Harrington Rare Disease Centre Advisory Board.

Key Points: 
  • Former U.K. Prime Minister David Cameron to lead the international efforts of the Accelerator as Chair of the Oxford-Harrington Rare Disease Centre Advisory Board.
  • The Accelerator is a first-in-kind, transatlantic initiative to identify, fund and advance breakthrough academic discoveries to deliver new treatments for the 400 million people worldwide who suffer from rare diseases.
  • The partners are also collaborating to create a dedicated Rare Disease Impact Fund to enable investments in mission-aligned projects and accelerate the development of rare disease therapeutics.
  • For academics and researchers to find out more about the Therapeutics Accelerator at the Oxford-Harrington Rare Disease Centre and how to apply, please go to OxfordHarrington.org .

The Oxford-Harrington Rare Disease Centre Launches Pioneering Therapeutics Accelerator to Advance Innovative Treatments for Rare Diseases

Retrieved on: 
Tuesday, October 3, 2023
Partnership, Disease, Drug development, University, Therapy, 100,000 Genomes Project, Rare disease, University Hospitals Cleveland Medical Center, Hope, University of Oxford, Research, Genomics, OHC, OXFORD, DSM-IV codes, Translation, Oxford Sciences Enterprises, MD, Patient, Investment, Cancer, Genomics England, Department of Biology, University of Oxford, Motivation, Accelerator, Foreign policy, Rare, Courage, Family, Harrington, Pharmaceutical industry, Hospital, Nursing, Vaccine, Management, Neuroscience, Medicine, Pediatrics

Former U.K. Prime Minister David Cameron to lead the international efforts of the Accelerator as Chair of the Oxford-Harrington Rare Disease Centre Advisory Board.

Key Points: 
  • Former U.K. Prime Minister David Cameron to lead the international efforts of the Accelerator as Chair of the Oxford-Harrington Rare Disease Centre Advisory Board.
  • The Accelerator is a first-in-kind, transatlantic initiative to identify, fund and advance breakthrough academic discoveries to deliver new treatments for the 400 million people worldwide who suffer from rare diseases.
  • The partners are also collaborating to create a dedicated Rare Disease Impact Fund to enable investments in mission-aligned projects and accelerate the development of rare disease therapeutics.
  • For academics and researchers to find out more about the Therapeutics Accelerator at the Oxford-Harrington Rare Disease Centre and how to apply, please go to OxfordHarrington.org .

Machine Discovery Secures $6 Million to Deliver AI Tools For Semiconductor Design

Retrieved on: 
Wednesday, September 27, 2023
University, UCSB Physics Department, CSO, BGF, OXFORD, Content discovery platform, Machine learning, Engineering, Growth, Video game, Manufacturing

First core application in analog semiconductor design, delivering instant prediction capability for integrated circuit design as a companion to existing tools and simulators.

Key Points: 
  • First core application in analog semiconductor design, delivering instant prediction capability for integrated circuit design as a companion to existing tools and simulators.
  • By 2026, Machine Discovery will cut the analog semiconductor product development cycle in half.
  • OXFORD, England and SANTA CLARA, Calif., Sept. 27, 2023 /PRNewswire/ -- Machine Discovery, a software company which uses machine learning technology to accelerate compute-intensive optimization and simulation tasks, has secured $6 million of funding.
  • Bijan Kiani, CEO of Machine Discovery, said: "Machine Discovery is pioneering the use of machine learning to reduce product development cycles in a variety of sectors.

Sophos Named the #1 Leader for MDR and Firewall by G2

Retrieved on: 
Tuesday, September 12, 2023
Sophos, XDR, Computation, Fire, OXFORD, Organization, EDR, MDR, Endpoint security, Firewall, Platform, Macs, Medical device, Risk management

OXFORD, United Kingdom, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sophos, a global leader in innovating and delivering cybersecurity as a service, today announced it has been named the number one overall global Leader for Managed Detection and Response (MDR) and Firewall Software in G2’s Fall 2023 Reports.

Key Points: 
  • as the Only Leader Across MDR, XDR, EDR, Endpoint Protection, and Firewall
    OXFORD, United Kingdom, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sophos , a global leader in innovating and delivering cybersecurity as a service, today announced it has been named the number one overall global Leader for Managed Detection and Response (MDR) and Firewall Software in G2’s Fall 2023 Reports .
  • Sophos ranks highest in 26 G2 reports spanning global regions and customer market segments, based on validated customer reviews.
  • Earning 114 total award badges, Sophos is once again the only Leader across MDR, Extended Detection and Response (XDR) Platforms , Endpoint Detection and Response (EDR), Endpoint Protection Suites , and Firewall Software.
  • “Right now, a goal for many organizations is to detect and stop threats faster in response to a growing trend of cybercriminals executing attacks with unprecedented speed.

Sophos Launches Incident Response Retainer

Retrieved on: 
Wednesday, August 23, 2023
IDC, Incident, Weakness, Research, OXFORD, Organization, MDR, Investment, Phoenix Technologies, Risk management, Sophos

OXFORD, United Kingdom, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Sophos, a global leader in innovating and delivering cybersecurity as a service, today announced its new Sophos Incident Response Retainer, which provides organizations with speedy access to Sophos’ industry-first fixed-cost incident response service that includes 45 days of 24/7 Managed Detection and Response (MDR). The retainer cuts red tape, allowing Sophos incident responders to quickly jump into active cyberattacks to investigate and remediate them. External vulnerability scanning and critical preparedness guidance are also included in the retainer, enabling organizations to proactively improve their existing security resilience by pinpointing and resolving issues that reduce the likelihood of a breach in the first place. 

Key Points: 
  • Shorter Attacker Dwell Times Require Faster Response, as Indicated in Sophos’ New Active Adversary Report for Tech Leaders
    OXFORD, United Kingdom, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Sophos , a global leader in innovating and delivering cybersecurity as a service, today announced its new Sophos Incident Response Retainer , which provides organizations with speedy access to Sophos’ industry-first fixed-cost incident response service that includes 45 days of 24/7 Managed Detection and Response (MDR).
  • The retainer cuts red tape, allowing Sophos incident responders to quickly jump into active cyberattacks to investigate and remediate them.
  • “Incident response retainers help organizations prepare in advance for the fastest response time possible to defend against active cyberattacks.
  • The only way to save time, reduce costs and mitigate the impact of a breach is to have an experienced incident response team in place and lined-up ready to go – before attackers strike.”
    The Sophos Incident Response Retainer is available in three tiers through Sophos partners worldwide.

Brainomix AI Technology Improves Access to Stroke Treatment across the NHS

Retrieved on: 
Tuesday, August 8, 2023
Communication, CT, A&E, Oxford, Disability, Stroke, Innovation, Brain, Oxford University Hospitals NHS Foundation Trust, OXFORD, Thrombectomy, MRI, Hospital, Patient, NHS Long Term Plan, Artificial intelligence, ISDN, AI, NHS, Oxford University Press, Software, Pharmaceutical industry, Medical imaging, Nursing, Health, Fellow of the Academy of Medical Sciences

Prompt recognition of this type of stroke and transfer to specialist centres for treatment is vital to ensure best possible outcomes for patients.

Key Points: 
  • Prompt recognition of this type of stroke and transfer to specialist centres for treatment is vital to ensure best possible outcomes for patients.
  • After Brainomix secured the NHS AI in Health and Care Award in 2020, the Oxford AHSN supported the spread and adoption of e-Stroke through participating Integrated Stroke Delivery Networks (ISDNs).
  • Feedback from NHS colleagues reported that the software is helping them to deliver a more efficient and effective stroke services for their patients.
  • We look forward to seeing more results as they come out, building on the largest real-world and independent evaluation of a stroke AI imaging platform."

A New Era For Motion Capture: Vicon Enters Markerless Market with Unparalleled Accuracy

Retrieved on: 
Tuesday, August 1, 2023
SIGGRAPH, Pioneer program, Visual effects, Partnership, Original equipment manufacturer, Collaboration, Audemars Piguet, ML, Research, Los Angeles Convention Center, OXFORD, VR, Dreamscape Immersive, Motion, Machine learning, Nature, Algorithm, Engineering, Source, VFX, Immersion, Virtual reality, Artificial intelligence, News, Video game, Television, Medical device, Management, Kverneland Group, Dreamscape

Commenting on the news, Imogen Moorhouse, Vicon CEO, said: "Today marks the beginning of a new era for motion capture.

Key Points: 
  • Commenting on the news, Imogen Moorhouse, Vicon CEO, said: "Today marks the beginning of a new era for motion capture.
  • The ability to capture motion without markers, while maintaining industry leading accuracy and precision, is an incredibly complex feat.
  • It is our first step towards future product launches which will culminate in a first-of-its-kind platform for markerless motion capture."
  • Vicon is aiming to enhance the potential for markerless motion capture, for the benefit of all.

Inspiring Tutor Opportunity Offered by Tutors International: Unique Primary Education Experience on a Mediterranean Yacht

Retrieved on: 
Monday, July 17, 2023
Teaching, Curriculum, Learning, Reading, Communication, Travel, Client, Drama, Acquisition, Family, Child, Water, OXFORD, Gymnastics, Tutoring

The renowned leader in full-time private tuition, Tutors International, seeks a creative and motivating primary Tutor to assist a family with their two young children onboard a yacht during a Mediterranean cruise.

Key Points: 
  • The renowned leader in full-time private tuition, Tutors International, seeks a creative and motivating primary Tutor to assist a family with their two young children onboard a yacht during a Mediterranean cruise.
  • This extraordinary opportunity requires a candidate to inspire and engage a 6-year-old girl and her lively 3-year-old brother during their summer voyage.
  • The primary focus of this role will be the 6-year-old girl, who is currently completing Year 1 in Australia.
  • The Client will provide the Tutor with a private cabin onboard the family yacht, complete with an en-suite bathroom.

Children Burnout Too: Private Tutoring Company Alarmed at Volume of Homework Given to Children

Retrieved on: 
Thursday, July 6, 2023
Parent, Learning, Caller, Mental health, Education, Blog, Love, OXFORD, Nursing, Tutoring

Adam Caller, the CEO of Tutors International, has called for a major overhaul of homework to address the growing issue of burnout in children.

Key Points: 
  • Adam Caller, the CEO of Tutors International, has called for a major overhaul of homework to address the growing issue of burnout in children.
  • Despite significant dialogue around adult burnout and workplace stress, Caller notes a lack of similar discussion in relation to children's education.
  • He advocates for a shift in our approach to homework, focusing on its judicious and purposeful use.
  • In his latest blog post, " Children Burnout Too: It’s Time to Minimise Homework ", he presents a compelling argument for reducing homework to mitigate burnout in children, an issue currently overlooked in the education sector.

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

Retrieved on: 
Wednesday, June 21, 2023
University of Oxford, EASL, Group 3, Clinical trial, Cancer, CHB, Autoimmunity, OXFORD, PBMC, Hepatitis B, Congress, Hepatitis, Medical research, Hepatology, ELISpot, Patient, Poster, Hepatitis B virus, European Association for the Study of the Liver, PD-1, HBV, Nivolumab, Vaccine, Liver, HBsAg

HBV002 (NCT04778904) is a Phase 1b/2a clinical trial of VTP-300 in adults with chronic Hepatitis B (CHB).

Key Points: 
  • HBV002 (NCT04778904) is a Phase 1b/2a clinical trial of VTP-300 in adults with chronic Hepatitis B (CHB).
  • “An effective immune response is likely to be essential to controlling chronic Hepatitis B,” said Meg Marshall, Vaccitech’s Chief Medical Officer.
  • VTP-300, encoding Hepatitis B virus (HBV) genotype C antigens, led to a decline in HBsAg in the majority of people infected with genotypes B and C viruses.
  • “Demonstrating cross-reactivity to genotypes B and C in participants, as well as to A-E in healthy subjects, is a promising step to being able to address chronic Hepatitis B infection in as many people as possible.”